ADORA CHATMAN: Open Payments
NPI 1659092690 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,183 in 18 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $155 · 2025 $1,183
Food & beverage: $1,183
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $286 |
| Eisai Inc. | 4 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $153 |
| Grifols USA, LLC | 1 | $128 |
| Novo Nordisk Inc | 1 | $123 |
| Lilly USA, LLC | 1 | $120 |
| Lundbeck LLC | 3 | $47 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Janssen Biotech, Inc. | 1 | $27 |
Products named: NUCALA, Leqembi, HYQVIA, Xembify, Ozempic, OMVOH, VYEPTI, CREXONT.
Industry payments across NY — which companies pay providers there.
